drugset / Trial / NCT03417076
Absolute Bioavailability Study With Bexagliflozin
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2018-09-16
- Completion
- 2018-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexagliflozin | Small molecule | 30 ug | Oral |
| Subject | Bexagliflozin | Small molecule | 20 mg | Oral |